ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,038Medicare Part D Prescriptions Filled, Including Refills

Rank: 14 out of 302

$1.39M Total Retail Price of All Prescriptions

Rank: 7 out of 302

800 Patients Receiving at Least One Drug in Part D
73% Patients 65 Years and Older
47% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Louisiana
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

4% of this provider’s 800 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

10% of this provider’s 800 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$138 was the average price of a prescription from this provider, compared to $83 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
GABAPENTIN 858 671 189 1 9
NAMENDA 529 495 85 2 44
HYDROCODONE-ACETAMINOPHEN 445 136 75 S3 3 1
CLOPIDOGREL 375 338 63 4 4
TOPIRAMATE 345 100 60 5 93
CARBIDOPA-LEVODOPA 343 315 53 6 109
LEVETIRACETAM 343 229 54 6 91
CYMBALTA 299 193 59 8 36
LYRICA 265 167 45 9 53
EXELON 235 205 50 10 107
DONEPEZIL HCL 211 184 42 11 67
ALPRAZOLAM 198 85 29 B 12 12
CLONAZEPAM 192 95 38 B 13 35
ROPINIROLE HCL 188 161 34 14 120
PRAMIPEXOLE DIHYDROCHLORIDE 143 111 25 15 143
PHENYTOIN SODIUM EXTENDED 141 75 20 16 153
PREDNISONE 137 132* 23 17 34
DILANTIN* 127 74 14 18 283
AGGRENOX 124 109 22 19 200
QUETIAPINE FUMARATE 123 81 21 A 20 43
BACLOFEN 123 37 21 20 114
OXYCODONE HCL 121 22 11 S2 22 45
VIMPAT 110 37 19 23 182
TRAMADOL HCL 107 87 23 24 21
TIZANIDINE HCL 107 17 20 24 42
ESCITALOPRAM OXALATE 105 55 26 26 40
DIAZEPAM 92 42 33 B 27 83
LIDOCAINE-PRILOCAINE 92 66 53 27 207
ZONISAMIDE 87 58 12 29 190
CARISOPRODOL 85 0 11 R 30 51
MIRTAZAPINE 85 51 13 30 172
PHENOBARBITAL 83 <11 <11 R 32 315
AMITRIPTYLINE HCL 82 66 23 R 33 76
CITALOPRAM HBR 78 46 18 34 57
CARBAMAZEPINE 75 29 14 35 155
CYCLOBENZAPRINE HCL 63 <11 16 R 36 86
PROPRANOLOL HCL 62 <11 <11 37 227
LAMOTRIGINE 61 <11 <11 38 122
AZILECT 61 <11 <11 38 304
PRIMIDONE 59 <11 <11 40 224
PYRIDOSTIGMINE BROMIDE 58 32 11 41 325
SUMATRIPTAN SUCCINATE 57 <11 15 42 259
MELOXICAM 57 25 18 42 29
LORAZEPAM 55 <11 <11 B 44 78
OXYCODONE HCL-ACETAMINOPHEN 55 <11 <11 S2 44 65
TEMAZEPAM 55 41 11 B 44 70
DIVALPROEX SODIUM 55 <11 <11 44 160
CARBIDOPA-LEVODOPA-ENTACAPONE 54 <11 <11 48 291
ENTACAPONE 51 <11 <11 49 348
CARBIDOPA-LEVODOPA ER 51 <11 <11 49 249
COPAXONE 51 <11 <11 49 444
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 28, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.